The integrated 40-gene expression profile (i40-GEP) combines tumor biology with clinicopathologic features to improve prognostic accuracy in high-risk cutaneous squamous cell carcinoma (HRcSCC).
i40-GEP categorizes patients into four risk classes, identifying those at highest risk (Class 2B) with significantly poorer 3-year metastasis-free survival.
Class 2B patients demonstrate a clear benefit from adjuvant radiation therapy (ART), supporting more personalized treatment approaches.
i40-GEP outperforms individual clinicopathologic factors in predicting metastasis and local recurrence, enabling improved clinical decision-making.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
